AcelRx rebrands to Talphera; ticker changes to TLPH Jan 10; Niyad PMA submission H2 2024

TALPHERA, INC.

Name changed from AcelRx Pharmaceuticals to Talphera, Inc.; new symbol TLPH effective Jan 10.
Rebranding reflects broader focus on medically supervised settings; lead candidate Niyad for dialysis circuit.
Niyad's registrational NEPHRO study to begin shortly; first patient expected Q1 2024.
PMA submission for Niyad targeted for H2 2024; product has FDA Breakthrough Designation.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

TALPHERA, INC.: Certificate of Amendment filed to change company name from AcelRx Pharmaceuticals, Inc. to Talphera, Inc (effective 2024-01-09).

Change: charter amendment
Effective: 2024-01-09

Exact text from the filing

On January 9, 2024, Talphera, Inc., formerly known as AcelRx Pharmaceuticals, Inc. (the “Company”), filed with the Secretary of State of the State of Delaware a Certificate of Amendment to the Company’s Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”), to change the name of the Company from “AcelRx Pharmaceuticals, Inc.” to “Talphera, Inc.” (the “Name Change”).

View on SEC.gov

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

TALPHERA, INC.: Amended and Restated Bylaws to reflect the new corporate name (effective 2024-01-09).

Change: bylaw amendment
Effective: 2024-01-09

Exact text from the filing

In connection with the Name Change, the Company amended its Amended and Restated Bylaws to reflect the new corporate name.

View on SEC.gov

13 governance changes filed in the last 30 days. Browse all governance changes →

TALPHERA, INC. filing history →

Source: SEC EDGAR

accession 0001437749-24-000938

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.